Advertisement
Advertisement

PTGX

PTGX logo

Protagonist Therapeutics, Inc

97.11
USD
Sponsored
-0.27
-0.27%
Jun 08, 14:22 UTC -4
Open

Protagonist Therapeutics, Inc Profile

About

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.

Info & Links

CEO

Dinesh V. Patel

Headquarters

7707 GATEWAY BLVD., SUITE 140
NEWARK, CA 94560, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.protagonist-inc.com

Auditor

Ernst & Young LLP

Share holders

2

Employees

132

Protagonist Therapeutics, Inc Statistics

Valuation Measures

Market Capitalization2

6.25B

Enterprise Value

6.05B

Enterprise Value/EBITDA(ttm)

-41.59

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

144.33

Price to Book(mrq)

10.59

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-282.83%

Profit Margin(ttm)

-524.94%

Return on Equity(ttm)

-19.89%

Return on Invested Capital(ttm)

-20.21%

Return on Assets(ttm)

-18.40%

Income Statement

Revenue(ttm)

74.06M

Revenue Per Share(ttm)

1.15

Gross Profit(ttm)

74.06M

EBITDA(ttm)3

-145.52M

Net Income Available to Common(ttm)

-114.71M

Diluted EPS(ttm)

-2.05

Share Statistics

Beta (5Y Monthly)

2.12

52-Week Change

78.59%

S&P 500 52-Week Change

23.76%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

64.31M

Dividend Yield

0.00%

Float4

60.68M

% Held by Insiders

4.90%

% Held by Institutions

98.63%

Balance Sheet

Total Cash(mrq)

547.79M

Total Cash Per Share(mrq)

8.52

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

12.71%

Quick Ratio(mrq)

12.71%

Book Value Per Share(mrq)

9.82

Cash Flow

Operating Cash Flow Per Share(ytd)

0.91

Free Cash Flow(ytd)

56.08M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement